Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavunalimab + Vudalimab in Refractory Metastatic Melanoma
NCT05695898Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bavunalimab in melanoma, sponsored by University of California, San Francisco. Primary endpoints: Number of Treatment-Emergent Adverse Events up to 24 months, Number of Treatment-Emergent Immune-Related Adverse Events up to 24 months and 1 more. Started Feb 2023; status: terminated.
02
Drugs
bavunalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05695898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695898.